LCI699
Total Payments
$2.0M
Transactions
198
Doctors
10
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $217,905 | 28 | 0 |
| 2019 | $413,551 | 35 | 0 |
| 2018 | $560,888 | 54 | 6 |
| 2017 | $770,474 | 81 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 135 | 99.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $10,586 | 1 | 0.5% |
| Travel and Lodging | $5,968 | 38 | 0.3% |
| Food and Beverage | $2,341 | 24 | 0.1% |
Payments by Type
Research
$1.9M
135 transactions
General
$18,895
63 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE III MULTI CENTER DOUBLE BLIND RANDOMIZED WITHDRAWAL STUDY OF LCI699 FOLLOWING A 24 WEEK SINGLE ARM OPEN LABEL DOSE TITRATION AND TREATMENT PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF LCI699 FOR THE TREATMENT OF PATIENTS WITH CUSHINGS DISEASE | Novartis Pharmaceuticals Corporation | $944,892 | 0 |
| A PHASE III MULTI CENTER RANDOMIZED DOUBLE BLIND 48 WEEK STUDY WITH AN INITIAL 12 WEEK PLACEBO CONTROLLED PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF OSILODROSTAT IN PATIENTS WITH CUSHINGS DISEASE | Novartis Pharmaceuticals Corporation | $759,197 | 0 |
| A PHASE I OPEN LABEL MULTI CENTER SINGLE DOSE PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF LCI699 IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION | Novartis Pharmaceuticals Corporation | $100,577 | 0 |
| A PROOF OF CONCEPT OPEN LABEL FORCED TITRATION MULTI CENTER STUDY TO ASSESS THE SAFETY AND OR TOLERABILITY AND EFFICACY OF 10 WEEKS TREATMENT OF LCI699 FOLLOWED BY A 12 WEEK TREATMENT PERIOD IN PATIENTS WITH CUSHINGS DISEASE | Novartis Pharmaceuticals Corporation | $77,300 | 0 |
| A PHASE III MULTI CENTER RANDOMIZED DOUBLE BLIND 48 WEEK STUDY WITH AN INITIAL 12 WEEK PLACEBO CONTROLLED PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF OSILODROSTAT IN PATIENTS WITH CUSHINGS DISEASE | NOVARTIS PHARMACEUTICALS CORPORATION | $31,277 | 0 |
| AN OPEN-LABEL, MULTI-CENTER, ROLL-OVER STUDY TO ASSESS LONG\NTERM SAFETY IN PATIENTS WITH ENDOGENOUS CUSHING???S\NSYNDROME WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED\NOSILODROSTAT (LCI699) STUDY AND ARE JUDGED BY THE\NINVESTIGATOR TO BENEFIT FROM CONTI | Novartis Pharmaceuticals Corporation | $20,096 | 0 |
| An open label, multicenter roll over study to assess long term safety in patients with endogenous Cushings syndrome who have completed a prior Novartis-sponsored nosilodrostat LCI699 study and are judged by the investigator to benefit from continued | NOVARTIS PHARMACEUTICALS CORPORATION | $10,585 | 0 |
Top Doctors Receiving Payments for LCI699
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $1.9M | 135 |
| , MD | Internal Medicine | Boston, MA | $10,977 | 3 |
| , MD | Endocrinology, Diabetes & Metabolism | Cincinnati, OH | $1,362 | 5 |
| , MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $1,309 | 7 |
| , MD | Endocrinology, Diabetes & Metabolism | Cleveland, OH | $1,211 | 9 |
| , MD | Endocrinology, Diabetes & Metabolism | New York, NY | $947.59 | 10 |
| , M.D | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $943.02 | 5 |
| , MD | Endocrinology, Diabetes & Metabolism | Worcester, MA | $889.17 | 10 |
| , MD | Endocrinology, Diabetes & Metabolism | Ann Arbor, MI | $888.46 | 9 |
| , MD | Endocrinology, Diabetes & Metabolism | Philadelphia, PA | $284.98 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Boston, MA | $83.80 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.0M
- Total Doctors 10
- Transactions 198
About LCI699
LCI699 is a drug associated with $2.0M in payments to 10 healthcare providers, recorded across 198 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $217,905 was paid across 28 transactions to 0 doctors.
The most common payment nature for LCI699 is "Unspecified" ($1.9M, 99.0% of total).
LCI699 is associated with 7 research studies, including "A PHASE III MULTI CENTER DOUBLE BLIND RANDOMIZED WITHDRAWAL STUDY OF LCI699 FOLLOWING A 24 WEEK SINGLE ARM OPEN LABEL DOSE TITRATION AND TREATMENT PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF LCI699 FOR THE TREATMENT OF PATIENTS WITH CUSHINGS DISEASE" ($944,892).